title: The soluble VEGF receptor 1 and 2 expression in cerebral spinal fluid as an indicator for leukemia central nervous system metastasis.
abstract: Over-expression of vascular endothelial growth factor A (VEGF-A) is correlated with leukemia metastasis. VEGF-A acts by binding to its membrane receptors R1 and R2 present in soluble forms (sVEGFR1, sVEGFR2) with different functions. sVEGFR could inhibit VEGF-A bioactivities, associated with favorable prognosis in solid tumors. However, its role is obscure in central nervous system leukemia (CNSL). The aim of this study was to investigate sVEGFR1, R2 as biomarkers in CNSL. Paired cerebrospinal fluid (CSF) and serum samples were collected from 35 leukemia cases with or without CNS metastasis. Levels of sVEGFR1 and sVEGFR2 in both CSF (sVEGFR1CSF, sVEGFR2CSF) and serum (sVEGFR1Serum, sVEGFR2Serum) were detected by ELISA. Other risk factors related to CNSL prognosis were also analyzed. sVEGFRSerum levels were 2.54-fold (sVEGFR1) and 25.6-fold (sVEGFR2) higher than sVEGFRCSF in both leukemic groups. sVEGFR1CSF in CNSL were 33 % higher than in the non-CNSL, and the levels of sVEGFR2CSF and sVEGFR2Serum had the same trend. Elevated sVEGFR1CSF and sVEGFR2CSF is closely correlated with blood-brain barrier (BBB) values and WBCCSF that is an indicator of CNSL disease burden. Cox regression analysis showed that the sVEGFR2CSF had a positive effect on event-free survival. Our data suggest that sVEGFR2CSF may be more potent than sVEGFR1CSF in predicting the outcome of leukemia patients, the balance between sVEGFR2CSF and VEGF-ACSF levels might be crucial for the progression of CNSL.
authors: Department of Hematology Laboratory, First Affiliated Hospital of Shantou University Medical College, 57 Changping Road, Shantou 515041, Guangdong, China.
authors: Yue-Ting
authors: YT
authors: Tang
authors: Fang
authors: F
authors: Jiang
authors: Li
authors: L
authors: Guo
authors: Meng-Ya
authors: MY
authors: Si
authors: Xiao-Yang
authors: XY
authors: Jiao
mesh_terms: D000293:Adolescent; D000328:Adult; D014408:Biomarkers, Tumor / Q000134:cerebrospinal fluid*; D016543:Central Nervous System Neoplasms / Q000134:cerebrospinal fluid* / Q000401:mortality / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D007938:Leukemia / Q000134:cerebrospinal fluid* / Q000401:mortality / Q000473:pathology; D008297:Male; D011379:Prognosis; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000134:cerebrospinal fluid*; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000134:cerebrospinal fluid*; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D040281:Vascular Endothelial Growth Factor Receptor-1; D040301:Vascular Endothelial Growth Factor Receptor-2
references: Cancer Res. 1997 Dec 1;57(23):5421-5
references: 9393770
references: Clin Immunol Immunopathol. 1997 Jan;82(1):12-7
references: 9000037
references: Br J Haematol. 2001 May;113(2):296-304
references: 11380392
references: Eur Cytokine Netw. 2003 Jul-Sep;14(3):149-53
references: 14656688
references: Int J Cancer. 2002 Mar 1;98(1):14-8
references: 11857378
references: Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10185-90
references: 18632559
references: Cancer. 2002 Nov 1;95(9):1923-30
references: 12404286
references: Cancer. 2004 May 1;100(9):1884-91
references: 15112269
references: Exp Mol Pathol. 2004 Apr;76(2):129-37
references: 15010291
references: J Immunol Methods. 1999 Jun 24;226(1-2):169-77
references: 10410982
references: Med Pediatr Oncol. 1986;14(3):191-4
references: 3528788
references: Patholog Res Int. 2010 Dec 29;2011:920509
references: 21253507
references: Med Sci Monit. 2006 Feb;12(2):CR45-50
references: 16449946
references: Nat Rev Mol Cell Biol. 2006 May;7(5):359-71
references: 16633338
references: Ann Intern Med. 1985 Oct;103(4):620-5
references: 3862359
references: J Clin Oncol. 2005 Feb 10;23(5):1011-27
references: 15585754
references: J Neurovirol. 2001 Dec;7(6):542-7
references: 11704886
references: PLoS One. 2011;6(8):e20599
references: 21857898
references: Blood. 2001 Sep 15;98(6):1904-13
references: 11535528
references: Cancer Sci. 2011 Apr;102(4):866-9
references: 21219538
references: Lung Cancer. 2006 Jul;53(1):91-6
references: 16697074
references: Clin Cancer Res. 2002 Sep;8(9):2856-61
references: 12231527
references: J Cereb Blood Flow Metab. 2007 Jun;27(6):1152-60
references: 17077813
references: Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8
references: 12516034
references: J Cell Mol Med. 2010 Jan;14(1-2):3-17
references: 19818095
references: Br J Dermatol. 2011 May;164(5):1061-70
references: 21198538
references: J Biol Chem. 2000 Jun 2;275(22):16986-92
references: 10747927
references: Surg Endosc. 2010 Feb;24(2):283-9
references: 19551437
references: J Immunol. 2005 Jan 1;174(1):215-22
references: 15611243
references: Nature. 2005 Dec 15;438(7070):923-5
references: 16355200
references: Cancer Res. 2009 Mar 15;69(6):2607-14
references: 19276374
references: Expert Rev Anticancer Ther. 2011 Apr;11(4):541-9
references: 21504321
references: PLoS One. 2009;4(4):e5108
references: 19352513
references: Cell Growth Differ. 2001 Mar;12(3):129-35
references: 11306513
references: J Cereb Blood Flow Metab. 2003 Jan;23(1):99-110
references: 12500095
references: Gynecol Oncol. 2007 Mar;104(3):557-63
references: 17150246
references: Endocr Rev. 2004 Aug;25(4):581-611
references: 15294883
references: Leuk Res. 2013 Apr;37(4):359-66
references: 23137522
references: Cancer Res. 2002 Feb 1;62(3):854-9
references: 11830543
references: Nat Med. 2003 Jun;9(6):669-76
references: 12778165